血小板聚集设备市场- 按产品类型（系统、试剂、消耗品和配件）、应用（研究、临床[心血管、骨科]）、最终用途（医院、诊断实验室、研究机构） - 全球预测，2024 年- 2032 年

在个人化医疗的强劲需求、不断升级的研发活动和不断增加的医疗保健支出的推动下，血小板聚集设备市场规模预计在 2024 年至 2032 年期间将以超过 8.9% 的复合年增长率增长。心血管疾病（CVD）仍然是全球死亡的主要原因，对医疗保健系统造成沉重负担。根据美国心臟病学会的数据，全球心血管疾病死亡人数从1990 年的1240 万人激增至2022 年的1980 万人。血管疾病发生率的不断上升。

血小板聚集装置在诊断和监测各种心血管疾病（包括血栓形成、心肌梗塞和中风）方面发挥着至关重要的作用。随着医疗保健提供者努力加强患者护理和改善治疗结果，对能够检测血小板功能障碍和准确评估血栓风险的先进诊断工具的需求不断增长。

血小板聚集装置市场分为产品类型、应用、最终用途和区域。

根据产品类型，试剂领域的行业规模预计从 2024 年到 2032 年将以 8.5% 的复合年增长率增长，因为它们在血小板聚集测试中发挥促进血小板聚集反应检测和量化的作用。这些试剂包括激动剂，例如二磷酸腺苷 (ADP)、花生四烯酸和胶原蛋白，它们可活化血小板受体并诱导血小板聚集。此外，具有增强特异性和敏感性的新型试剂的开发正在推动血小板聚集设备的创新，使临床医生能够根据个别患者情况量身定制治疗方案并优化治疗结果。

在应用方面，研究领域的血小板聚集设备产业预计到2032年将实现8.6%的复合年增长率。血小板聚集设备的应用铺平道路。此外，将血小板聚集测试整合到转化研究和临床试验中，有助于识别疾病预后和治疗反应的生物标记物，进一步推动该领域的成长。

在快速城市化、人口老化和医疗保健支出增加的推动下，到 2032 年，亚太地区血小板聚集设备产业的复合年增长率预计将达到 10.6%。中国、印度和日本等国家的心血管疾病盛行率激增，进一步推动了先进诊断和监测解决方案的需求。大量患者的存在以及人们对预防性医疗措施的认识不断增强，也为该地区采用血小板聚集设备创造了有利条件。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 慢性病发生率上升
    • 血小板聚集仪的技术进步
    • 心血管疾病相关患者人数不断增加
  • 产业陷阱与挑战
    • 设备成本高，技术人员短缺
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

• 主要趋势
• 系统
• 试剂
• 耗材及配件

第 6 章：市场估计与预测：按应用分类，2018 年 - 2032 年

• 主要趋势
• 研究应用
• 临床应用
  • 心血管应用
  • 骨科应用
  • 其他临床应用

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 诊断实验室
• 研究和学术机构
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• AggreDyne, Inc.
• Bio/Data Corporation
• Chrono-Log Corporation
• Drucker Diagnostics
• F. Hoffmann-La Roche Ltd.
• Haemonetics Corporation
• Helena Laboratories Corporation
• Siemens Healthineers AG
• Sienco, Inc.
• Sysmex Corporation
• Werfen

Platelet Aggregation Devices Market size is expected to grow at over 8.9% CAGR during 2024-2032, driven by the strong demand for personalized medicine, escalating R&D activities, and increasing healthcare expenditure. Cardiovascular diseases (CVDs) continue to be a leading cause of mortality worldwide, holding a substantial burden on healthcare systems. According to American College of Cardiology, the global death toll from cardiovascular diseases surged from 12.4 million in 1990 to 19.8 million in 2022. Sedentary lifestyles, unhealthy dietary habits, and increasing geriatric population are adding to the escalating incidence of CVDs globally.

Platelet aggregation devices play a crucial role in diagnosing and monitoring various cardiovascular conditions, including thrombosis, myocardial infarction, and stroke. As healthcare providers strive to enhance patient care and improve outcomes, there is a growing demand for advanced diagnostic tools capable of detecting platelet dysfunction and assessing thrombotic risk accurately.

The platelet aggregation devices market is classified into product type, application, end-use and region.

Based on product type, the industry size from the reagents segment is expected to grow at 8.5% CAGR from 2024 to 2032, owing to their role in platelet aggregation testing to facilitate the detection and quantification of platelet aggregation responses. These reagents include agonists, such as adenosine diphosphate (ADP), arachidonic acid, and collagen, which activate platelet receptors and induce platelet aggregation. Furthermore, the development of novel reagents with enhanced specificity and sensitivity is driving innovations in platelet aggregation devices, enabling clinicians to tailor treatment regimens based on individual patient profiles and optimize therapeutic outcomes.

In terms of application, the platelet aggregation devices industry from the research segment is poised to record 8.6% CAGR up to 2032. Researchers are increasingly utilizing platelet aggregation devices to investigate the mechanisms underlying thrombosis, hemostasis, and platelet dysfunction, paving the way for the development of novel therapeutic targets and interventions. Moreover, the integration of platelet aggregation testing into translational research studies and clinical trials is facilitating the identification of biomarkers for disease prognosis and treatment response, further driving the segment growth.

Asia Pacific platelet aggregation devices industry is set to gain traction at 10.6% CAGR till 2032, fueled by rapid urbanization, aging population, and increasing healthcare expenditure. Countries, such as China, India, and Japan are witnessing a surge in the prevalence of cardiovascular diseases, further driving the demand for advanced diagnostic and monitoring solutions. The presence of a large patient pool and growing awareness about preventive healthcare measures are also creating favorable conditions for the adoption of platelet aggregation devices in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic diseases
    • 3.2.1.2 Technological advancements in platelet aggregometers
    • 3.2.1.3 Growing patient population related to cardiovascular diseases
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of devices and shortage of skilled personnel
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Systems
• 5.3 Reagents
• 5.4 Consumables and accessories

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Research applications
• 6.3 Clinical applications
  • 6.3.1 Cardiovascular applications
  • 6.3.2 Orthopedic applications
  • 6.3.3 Other clinical applications

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Diagnostic laboratories
• 7.4 Research and academic institutes
• 7.5 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AggreDyne, Inc.
• 9.2 Bio/Data Corporation
• 9.3 Chrono-Log Corporation
• 9.4 Drucker Diagnostics
• 9.5 F. Hoffmann-La Roche Ltd.
• 9.6 Haemonetics Corporation
• 9.7 Helena Laboratories Corporation
• 9.8 Siemens Healthineers AG
• 9.9 Sienco, Inc.
• 9.10 Sysmex Corporation
• 9.11 Werfen